– DelveInsight launched a new report on Parkinson’s Disease Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report
1. The total diagnosed Parkinson’s Disease prevalent population in the 7MM is expected to rise to 3,284,084 in 2030, during the study period [2017–2030].2. The highest diagnosed Parkinson’s Disease prevalent population was in the United States.3. Males are more prominent for developing Parkinson’s Disease in comparison to female.4. Primary Parkinsonism or Idiopathic Parkinson’s cases are prominent in comparison to Secondary or atypical parkinsonism.
Key benefits of the report1. Parkinson’s Disease market report covers a descriptive overview and comprehensive insight of the Parkinson’s Disease epidemiology and Parkinson’s Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Parkinson’s Disease market report provides insights into the current and emerging therapies.3. Parkinson’s Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Parkinson’s Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Parkinson’s Disease market.
Request for sample pages
There is currently no cure, but Parkinson’s Disease treatments are available to help relieve the symptoms and maintain the quality of life. Parkinson’s Disease treatments include supportive therapies (physiotherapy), medication, and surgery (for some people). The medication can be used to benefit the main symptoms of Parkinson’s disease, such as shaking (tremors) and movement problems. Three main types of medication are- Carbidopa-levodopa, Carbidopa-levodopa infusion, and Dopamine agonists.
The present Parkinson’s Disease treatment options include medication, surgery, complementary and supportive therapies. The approved medication therapies are categorized into seven groups that include Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), Catechol O-methyltransferase (COMT) inhibitors (Tasmar, Comtan), Anticholinergics (Cogentin, Artane), and Amantadine.
The most frequently prescribed combination drugs are carbidopa/levodopa (cocareldopa [sinemet, pharmacopa, atamet]) and benserazide/levodopa (co-beneldopa [Madopar]). More recently, continuous intestinal infusion of levodopa gel (Duodopa [AbbVie Limited]) has shown to be effective in terms of decreasing severe motor fluctuations when compared to oral levodopa. However, this treatment is currently prohibitively expensive for widespread use. Levodopa with a DOPA decarboxylase inhibitor is usually a first-line treatment option for Parkinson’s disease.
The present treatment options include medication, surgery, complementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy). The approved medication therapies are categorized into seven groups that include Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), Catechol O-methyltransferase (COMT) inhibitors (Tasmar, Comtan), Anticholinergics (Cogentin, Artane), and Amantadine.
The most frequently prescribed combination drugs are carbidopa/levodopa (cocareldopa [sinemet, pharmacopa, atamet]) and benserazide/levodopa (co-beneldopa [Madopar]). More recently, continuous intestinal infusion of levodopa gel (Duodopa [AbbVie Limited]) has shown to be effective in terms of decreasing severe motor fluctuations when compared to oral levodopa. However, this treatment is currently prohibitively expensive for widespread use. Levodopa with a DOPA decarboxylase inhibitor is usually a first-line treatment option for Parkinson’s disease. For patients with advanced Parkinson’s disease, most surgeries are preferred.
The launch of the emerging therapies is expected to significantly impact Parkinson’s Disease treatment scenario in the upcoming years:-Drugs covered1. Apomorphine Infusion2. Accordion Pill Carbidopa/Levodopa3. APL–1302774. P2B0015. IPX2036. LY030037. ABBV-951And many others
The key players in Parkinson’s Disease market are:1. US WorldMeds LLC2. Intec Pharma3. Sunovion Pharma4. Pharma Two B Ltd5. Impax Laboratories6. Luye Pharma7. AbbVieAnd many others
Table of contents1. Key Insights2. Parkinson’s Disease Market Overview at a Glance3. Parkinson’s Disease Background and Overview4. Parkinson’s Disease Epidemiology and Patient Population5. Country Wise Parkinson’s Disease Epidemiology5.1. United States Epidemiology5.2. EU-5 Epidemiology5.2.1. Germany5.2.2. France5.2.3. Italy5.2.4. Spain5.2.5. United Kingdom5.3. Japan Epidemiology6. Parkinson’s Disease Treatment and Management7. Unmet Needs8. Parkinson’s Disease Marketed Drugs8.1. Key Cross of Marketed Drugs8.2. Profiles of Some of the Marketed Drugs8.3. Istradefylline (KW6002): Kyowa Kirin8.4. Opicapone: BIAL8.5. Gocovri: Adamas Pharmaceuticals8.6. Xadago: Zambon SpA8.7. Osmolex ER: Osmotica Pharmaceutical8.8. Duopa (Duodopa, ABT-SLV187): AbbVie8.9. Rytary: Impax Laboratories8.10. Inbrija: Acorda Therapeutics8.11. Nuplazid: ACADIA Pharmaceuticals Inc.9. Parkinson’s Disease Emerging Drugs9.1. Key Cross of Emerging Drugs9.2. Apomorphine Infusion: US WorldMeds LLC9.3. Accordion Pill Carbidopa/Levodopa: Intec Pharma9.4. APL–130277: Sunovion Pharma9.5. P2B001: Pharma Two B Ltd.9.6. IPX203: Impax Laboratories9.7. LY03003: Luye Pharma9.8. ABBV-951: AbbVie9.9. NTCELL Implantation: Living Cell Technologies9.10. Nilotinib: Novartis9.11. Solriamfetol (JZP-110): Jazz Pharmaceuticals9.11.1. Product Description9.11.2. Other Developmental Activities9.11.3. Clinical Development9.12. VY-AADC: Neurocrine Biosciences/Voyager Therapeutics9.13. OXB-102 (AXO-Lenti-PD): Axovant Sciences9.14. ND0612: NeuroDerm9.15. ITI-214: Intracellular Therapies9.16. IRL752: Integrative Research Laboratories AB (IRLAB)10. Parkinson’s Disease 7 Major Market Analysis11. Market Outlook: The United States11.1. United States Market Size11.2. Market Outlook: Europe11.2.1. Germany11.2.2. France11.2.3. Italy11.2.4. Spain11.2.5. United Kingdom11.3. Market Outlook: Japan12. Market Drivers13. Market Barriers14. SWOT Analysis15. Appendix16. DelveInsight Capabilities17. Disclaimer18. About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:[email protected]+919650213330SOURCE DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/